Jason Karamchandani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jason Karamchandani has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Ashot S. Harutyunyan
Department of Human Genetics, McGill University, Montreal, Quebec, Canada
17 shared publications - Carol C.L. Chen
Department of Human Genetics, McGill University, Montréal, QC, H3A 0C7, Canada
17 shared publications - Claudia L. Kleinman
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
17 shared publications - Damien Faury
Department of Human Genetics, McGill University Health Center Research Institute
17 shared publications - Dylan M. Marchione
Department of Biochemistry and Biophysics, and Penn Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
17 shared publications Leonie G. Mikael
17 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in Neuroimage: Reports
- Vol. 6 (4)
Robustness of MEG source imaging in pediatric patients with surgical cavities: A case series
- 23 October 2026
- Published by Elsevier in Neuroimage: Reports
- Vol. 6 (4)
Open AccessRobustness of MEG source imaging in pediatric patients with surgical cavities: A case series
- Open Access
AMPD2 deficiency implicates cytosolic purine metabolism in the pathogenesis of Leigh syndrome
Importance: Cellular mechanisms underlying mitochondrial dysfunction, a hallmark feature of many neurodegenerative conditions, remain incompletely understood, and their true diversity is unknown. Objective: To identify and functionally validate novel genetic variants causative of Leigh syndrome. Design: We performed whole genome sequencing (WGS) and first-degree relative genotyping on two unrelated adult subjects with brain MRI abnormalities evoking Leigh syndrome. Blue native polyacrylamide gel electrophoresis (BN-PAGE) and respiratory chain enzymatic activity assays were performed to screen for respiratory complex assembly and/or oxidative phosphorylation impairments. Cells obtained from patient dermal and muscular biopsies were immortalized and later genetically corrected to evaluate cellular response to metabolic stress. Setting: Subjects were recruited from The Neuro (McGill University), Rizk Hospital (Lebanese American University), and Centre Hospitalier Universitaire Sainte-Justine (University of Montreal). Research connections were established through the White Matter Rounds Network and GeneMatcher. Participants: Four subjects representing three families with undiagnosed Leigh syndrome (age range 10-40 years) were ultimately recruited. Main outcome(s) and Measure(s): DNA sequencing uncovered a new autosomal recessive Leigh syndrome-associated gene that was functionally validated. Results: Bi-allelic pathogenic variants in AMPD2 were detected in all subjects. BN-PAGE of patient skeletal muscle mitochondria captured an isolated complex V assembly defect in the context of heavy mTOR activation, while the accompanying enzymological assays reported decreased activities of complexes I and IV. Opposite to controls, patient-derived cell lines and muscle lacked AMPD2 protein, attributing null status to the variants detected. During metabolic challenge, only mutant cells suffered from mitochondrial hyperfusion and high-order cytosolic IMPDH2 oligomerization, implying simultaneous ATP accumulation and GTP deficiency. However, under these conditions, both complex V assembly and mTOR status in mutant cells and myotubes remained unchanged relative to the corrected lines. All mutant phenotypes observed collectively reverted upon exogenous introduction of wild-type AMPD2. Conclusions and Relevance: The recognition of AMPD2 -related Leigh syndrome ( AMPD2 -LS) as a novel entity provides strong evidence for classifying AMPD2 deficiency as a mitochondrial disease. Our data suggest that respiratory capacity is significantly modulated by AMPD2, a cytosolic enzyme selectively regulating complex V assembly through an elusive process. Key points: Question: Do AMPD2 mutations cause mitochondrial disease? Findings: In this case series, we found that four subjects from three families with molecularly unexplained Leigh syndrome carried bi-allelic, loss-of-function variants in AMPD2 , a gene not previously linked to mitochondrial disease. Biochemical analyses uncovered an isolated complex V assembly defect, providing diagnostic confirmation of a new entity: AMPD2 -related Leigh syndrome ( AMPD2 -LS). Meaning: The cytosolic purine cycle is a primordial determinant of oxidative phosphorylation and mitochondrial health.
Open AccessAMPD2 deficiency implicates cytosolic purine metabolism in the pathogenesis of Leigh syndrome
Importance: Cellular mechanisms underlying mitochondrial dysfunction, a hallmark feature of many neurodegenerative conditions, remain incompletely understood, and their true diversity is unknown. Objective: To identify and functionally validate novel genetic variants causative of Leigh syndrome. Design: We performed whole genome sequencing (WGS) and first-degree relative genotyping on two unrelated adult subjects with brain MRI abnormalities evoking Leigh syndrome. Blue native polyacrylamide gel electrophoresis (BN-PAGE) and respiratory chain enzymatic activity assays were performed to screen for respiratory complex assembly and/or oxidative phosphorylation impairments. Cells obtained from patient dermal and muscular biopsies were immortalized and later genetically corrected to evaluate cellular response to metabolic stress. Setting: Subjects were recruited from The Neuro (McGill University), Rizk Hospital (Lebanese American University), and Centre Hospitalier Universitaire Sainte-Justine (University of Montreal). Research connections were established through the White Matter Rounds Network and GeneMatcher. Participants: Four subjects representing three families with undiagnosed Leigh syndrome (age range 10-40 years) were ultimately recruited. Main outcome(s) and Measure(s): DNA sequencing uncovered a new autosomal recessive Leigh syndrome-associated gene that was functionally validated. Results: Bi-allelic pathogenic variants in AMPD2 were detected in all subjects. BN-PAGE of patient skeletal muscle mitochondria captured an isolated complex V assembly defect in the context of heavy mTOR activation, while the accompanying enzymological assays reported decreased activities of complexes I and IV. Opposite to controls, patient-derived cell lines and muscle lacked AMPD2 protein, attributing null status to the variants detected. During metabolic challenge, only mutant cells suffered from mitochondrial hyperfusion and high-order cytosolic IMPDH2 oligomerization, implying simultaneous ATP accumulation and GTP deficiency. However, under these conditions, both complex V assembly and mTOR status in mutant cells and myotubes remained unchanged relative to the corrected lines. All mutant phenotypes observed collectively reverted upon exogenous introduction of wild-type AMPD2. Conclusions and Relevance: The recognition of AMPD2 -related Leigh syndrome ( AMPD2 -LS) as a novel entity provides strong evidence for classifying AMPD2 deficiency as a mitochondrial disease. Our data suggest that respiratory capacity is significantly modulated by AMPD2, a cytosolic enzyme selectively regulating complex V assembly through an elusive process. Key points: Question: Do AMPD2 mutations cause mitochondrial disease? Findings: In this case series, we found that four subjects from three families with molecularly unexplained Leigh syndrome carried bi-allelic, loss-of-function variants in AMPD2 , a gene not previously linked to mitochondrial disease. Biochemical analyses uncovered an isolated complex V assembly defect, providing diagnostic confirmation of a new entity: AMPD2 -related Leigh syndrome ( AMPD2 -LS). Meaning: The cytosolic purine cycle is a primordial determinant of oxidative phosphorylation and mitochondrial health.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (6) , e200103
mTOR Pathway Somatic Pathogenic Variants in Focal Malformations of Cortical Development
Background and Objectives Somatic and germline pathogenic variants in genes of the mammalian target of rapamycin (mTOR) signaling pathway are a common mechanism underlying a subset of focal malformations of cortical development (FMCDs) referred to as mTORopathies, which include focal cortical dysplasia (FCD) type II, subtypes of polymicrogyria, and hemimegalencephaly. Our objective is to screen resected FMCD specimens with mTORopathy features on histology for causal somatic variants in mTOR pathway genes, describe novel pathogenic variants, and examine the variant distribution in relation to neuroimaging, histopathologic classification, and clinical outcomes. Methods We performed ultra-deep sequencing using a custom HaloPlexHS Target Enrichment kit in DNA from 21 resected fresh-frozen histologically confirmed FCD type II, tuberous sclerosis complex, or hemimegalencephaly specimens. We mapped the variant alternative allele frequency (AAF) across the resected brain using targeted ultra-deep sequencing in multiple formalin-fixed paraffin-embedded tissue blocks. We also functionally validated 2 candidate somatic MTOR variants and performed targeted RNA sequencing to validate a splicing defect associated with a novel DEPDC5 variant. Results We identified causal mTOR pathway gene variants in 66.7% (14/21) of patients, of which 13 were somatic with AAF ranging between 0.6% and 12.0%. Moreover, the AAF did not predict balloon cell presence. Favorable seizure outcomes were associated with genetically clear resection borders. Individuals in whom a causal somatic variant was undetected had excellent postsurgical outcomes. In addition, we demonstrate pathogenicity of the novel c.4373_4375dupATG and candidate c.7499T>A MTOR variants in vitro. We also identified a novel germline aberrant splice site variant in DEPDC5 (c.2802-1G>C). Discussion The AAF of somatic pathogenic variants correlated with the topographic distribution, histopathology, and postsurgical outcomes. Moreover, cortical regions with absent histologic FCD features had negligible or undetectable pathogenic variant loads. By contrast, specimens with frank histologic abnormalities had detectable pathogenic variant loads, which raises important questions as to whether there is a tolerable variant threshold and whether surgical margins should be clean, as performed in tumor resections. In addition, we describe 2 novel pathogenic variants, expanding the mTORopathy genetic spectrum. Although most pathogenic somatic variants are located at mutation hotspots, screening the full-coding gene sequence remains necessary in a subset of patients.
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (6) , e200103
Open AccessmTOR Pathway Somatic Pathogenic Variants in Focal Malformations of Cortical Development
Background and Objectives Somatic and germline pathogenic variants in genes of the mammalian target of rapamycin (mTOR) signaling pathway are a common mechanism underlying a subset of focal malformations of cortical development (FMCDs) referred to as mTORopathies, which include focal cortical dysplasia (FCD) type II, subtypes of polymicrogyria, and hemimegalencephaly. Our objective is to screen resected FMCD specimens with mTORopathy features on histology for causal somatic variants in mTOR pathway genes, describe novel pathogenic variants, and examine the variant distribution in relation to neuroimaging, histopathologic classification, and clinical outcomes. Methods We performed ultra-deep sequencing using a custom HaloPlexHS Target Enrichment kit in DNA from 21 resected fresh-frozen histologically confirmed FCD type II, tuberous sclerosis complex, or hemimegalencephaly specimens. We mapped the variant alternative allele frequency (AAF) across the resected brain using targeted ultra-deep sequencing in multiple formalin-fixed paraffin-embedded tissue blocks. We also functionally validated 2 candidate somatic MTOR variants and performed targeted RNA sequencing to validate a splicing defect associated with a novel DEPDC5 variant. Results We identified causal mTOR pathway gene variants in 66.7% (14/21) of patients, of which 13 were somatic with AAF ranging between 0.6% and 12.0%. Moreover, the AAF did not predict balloon cell presence. Favorable seizure outcomes were associated with genetically clear resection borders. Individuals in whom a causal somatic variant was undetected had excellent postsurgical outcomes. In addition, we demonstrate pathogenicity of the novel c.4373_4375dupATG and candidate c.7499T>A MTOR variants in vitro. We also identified a novel germline aberrant splice site variant in DEPDC5 (c.2802-1G>C). Discussion The AAF of somatic pathogenic variants correlated with the topographic distribution, histopathology, and postsurgical outcomes. Moreover, cortical regions with absent histologic FCD features had negligible or undetectable pathogenic variant loads. By contrast, specimens with frank histologic abnormalities had detectable pathogenic variant loads, which raises important questions as to whether there is a tolerable variant threshold and whether surgical margins should be clean, as performed in tumor resections. In addition, we describe 2 novel pathogenic variants, expanding the mTORopathy genetic spectrum. Although most pathogenic somatic variants are located at mutation hotspots, screening the full-coding gene sequence remains necessary in a subset of patients.
- Open Access
Comparative Analysis of Methods to Reduce Activation Signature Gene Expression in PBMCs
Summary: Preserving the in vivo cell transcriptome is essential for accurate profiling, yet factors during cell isolation including time ex vivo and temperature induce artifactual gene expression, particularly in stress-responsive immune cells. In this study, we investigated two methods to mitigate ex vivo activation signature gene (ASG) expression in peripheral blood mononuclear cells (PBMCs): transcription and translation inhibitors (TTis) and cold temperatures during isolation. Comparative analysis of PBMCs isolated with TTis revealed reduced ASG expression. However, TTi treatment impaired responsiveness to LPS stimulation in subsequent in vitro experiments. In contrast, cold isolation methods also prevented ASG expression; up to a point where the addition of TTis during cold isolation offered minimal additional advantage. These findings highlight the importance of considering the advantages and drawbacks of different isolation methods to ensure accurate interpretation of PBMC transcriptomic profiles. Highlights: Traditional room temperature isolation methods trigger activation signature gene expression in PBMCs, even when rapidly isolated, whereas 4°C isolation methods do not. Transcription and translation inhibitors and cold processing techniques reduce activation signature gene expression via shared mechanisms. PBMCs treated with transcription and translation inhibitors lose responsiveness to external stimuli. Cold isolation methods offer a suitable and inexpensive alternative to mitigate activation signature gene expression in PBMCs.
Open AccessComparative Analysis of Methods to Reduce Activation Signature Gene Expression in PBMCs
Summary: Preserving the in vivo cell transcriptome is essential for accurate profiling, yet factors during cell isolation including time ex vivo and temperature induce artifactual gene expression, particularly in stress-responsive immune cells. In this study, we investigated two methods to mitigate ex vivo activation signature gene (ASG) expression in peripheral blood mononuclear cells (PBMCs): transcription and translation inhibitors (TTis) and cold temperatures during isolation. Comparative analysis of PBMCs isolated with TTis revealed reduced ASG expression. However, TTi treatment impaired responsiveness to LPS stimulation in subsequent in vitro experiments. In contrast, cold isolation methods also prevented ASG expression; up to a point where the addition of TTis during cold isolation offered minimal additional advantage. These findings highlight the importance of considering the advantages and drawbacks of different isolation methods to ensure accurate interpretation of PBMC transcriptomic profiles. Highlights: Traditional room temperature isolation methods trigger activation signature gene expression in PBMCs, even when rapidly isolated, whereas 4°C isolation methods do not. Transcription and translation inhibitors and cold processing techniques reduce activation signature gene expression via shared mechanisms. PBMCs treated with transcription and translation inhibitors lose responsiveness to external stimuli. Cold isolation methods offer a suitable and inexpensive alternative to mitigate activation signature gene expression in PBMCs.